Article Text
PDF
Abstract
Background There are high rates registered globally of breast cancer, cervical and prostate. People going through have needs that cause an impact in their life’s quality, especially in the final stages of the illness.
Goal To characterise the most evaluated and afflicted physical, emotional, roll, cognitive, social and spiritual needs of patients in the final stages of breast, cervical and prostate cancer.
Interventions/Methods A thorough systematic search of databases such as Medline (Ovid) and Embase, from databases’ creation throughout 31 December 2021. Quantitative studies were included to evaluate, from the adoption of tools, the dimensions or needs of people going under three types of cancer on final stages.
Results Twelve studies were included. More common symptoms such as nausea/vomiting and pain were the most evaluated with 83%. Fifty-eight per cent of papers studied the emotional function of people with breast and prostate cancer. Other 42% included roll, cognitive and social appreciations. Sexual, cognitive and physical, in that line, were the most affected. The most common questionnaires used to measure oncological patients on final stages were those from European Organisation for Research and Treatment of Cancer on its C-30, BR-23, C-15 PAL and CR-25 versions.
Conclusions On breast and prostate cancer, the most affected aspect was the sexual dysfunction, while for cervical cancer, the physical function was the most altered one. Spiritual dimension was not included in any of the evaluated literature.
- Cancer
- Breast
- Prostate
- Terminal care
- Hospice care
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
Statistics from Altmetric.com
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
Footnotes
Twitter @cesarjosevelap, @herneygarcia
Contributors Study design: YKPS, GAMU, CVP, HAGP, JEPP. Literature search: YKPS, GAMU, JEPP. Quality assessment: YKPS, GAMU, JEPP. Analysis and interpretation: YKPS, GAMU, CVP, HAGP, JEPP. Manuscript writing: YKPS, GAMU, CVP, HAGP, JEPP. Critical revisions for important intellectual content: YKPS, GAMU, CVP, HAGP, JEPP. Overall content as the guarantor: YKPS. All authors were involved in drafting this manuscript and have read and approved the final version.
Funding Present research was financially sponsored with Royalties System BPIN 2020000100053.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.